celecoxib + rofecoxib

This is a hypothetical or non-standard combination of two selective cyclooxygenase-2 (COX‑2) inhibitors, celecoxib and rofecoxib. Both are small molecule nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the COX‑2 enzyme, reducing inflammation and pain with less gastrointestinal toxicity than traditional NSAIDs. Celecoxib is approved for osteoarthritis, rheumatoid arthritis, acute pain, dysmenorrhea, and to reduce polyps in familial adenomatous polyposis. Rofecoxib was used similarly but was withdrawn from global markets in 2004 due to increased cardiovascular risk. Both act by inhibiting prostaglandin synthesis via COX‑2 blockade[1][3][5][6].

Brand names

Celebrex (for celecoxib)Vioxx (for rofecoxib)Ceoxx (for rofecoxib)Ceeoxx (for rofecoxib)